Navigation Links
OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
Date:5/28/2008

HONG KONG, May 28 /PRNewswire/ -- OrbusNeich today announced that it has received approval from the Department of Health to market the Genous Bio-engineered R stent in Taiwan.

The Genous stent is coated with an antibody to capture a patient's endothelial progenitor cells (EPCs) circulating in the bloodstream. When attracted to the inner surface of the Genous stent, EPCs have been shown to quickly form a healthy layer of endothelium that minimizes stent restenosis and provides protection against stent thrombosis.

"We are pleased to be able to offer the Genous stent to interventional cardiologists in Taiwan," said Teddy Chien, OrbusNeich's chairman. "The introduction of our pro-healing stent to the Taiwanese market is an important step for our company as we expand our presence in the Asia-Pacific region. Based on our interaction with Taiwanese physicians, we expect strong Genous sales from the outset because of the demand for safe alternatives to drug-eluting stents."

An estimated 20,000 coronary angioplasty procedures will be performed in Taiwan in 2008, 60% of which are expected to involve the use of drug eluting or coated stents.

"We are pleased to have Genous stents become available in Taiwan," said Jui-Sung Hung, M.D., FACC, FAHA, founding President of the Taiwan Society of Cardiovascular Interventions. "Preliminary studies have shown that the use of Genous stents is as safe and effective as TAXUS DES, and more importantly, that the stent thrombosis rate at 12 months is lower with the Genous stent despite one month of dual antiplatelet therapy. Although results of large-scale, randomized control trials are awaited to make more definitive conclusions, I believe Genous will be a good treatment option for patients who cannot undergo long-term dual antiplatelet therapy or patients who have increased risk of thrombotic events."

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

As a global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
2. OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation Catheter
3. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
4. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
5. Cornell receives federal grants to create fabrics to render toxic chemicals harmless
6. Einstein-Montefiore Center for AIDS Research receives $8.5M award from NIH
7. Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling
8. TriWest Receives National Awards for Innovative Video Communications to Military Community
9. A.S.V., Inc. Receives Safety and Health Award
10. Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence
11. LMI Receives CDC/ATSDR Public Health Improvement Award for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... On February 22, ... a letter to withdraw previous guidance issued by the Obama Administration requiring ... issued in May 2016 by the Obama Administration came in response to a ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in Miami Beach to host its Swirl: Miami Wine Tasting Event on March ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... The American ... for ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. ... an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, ... raffle. Throughout the month of February, patients who visit Hamlin Dental Group will receive ... dinner for two at the Cheesecake Factory. , Tickets are available for routine ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... Feb. 23, 2017  The particle counters market ... 2021 from USD 275.9 million in 2016, at ... full report: http://www.reportlinker.com/p04718602-summary/view-report.html The ... pharmaceutical R&D, and growth in manufacturing industries in ... growth for particle counters. On the other hand, ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis and ... global Urinary Incontinence market. The research answers the following questions: ... for Urinary Incontinence and their clinical attributes? How are they positioned ...
Breaking Medicine Technology: